Tailoring chemo by genetics and health may boost survival in older AML patients

NCT ID NCT03226418

Completed Disease control Sponsor: University of Nebraska Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether matching chemotherapy intensity to a patient's genetic risk and overall health could improve outcomes for older adults (60+) with acute myeloid leukemia. 75 participants received either standard intensive or lower-intensity chemo based on their individual risk profile. Researchers tracked remission rates, survival, and quality of life for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytarabine (chemotherapy)
What this could lead to: If successful, this approach could help doctors choose the right chemotherapy intensity for older AML patients, potentially improving survival and quality of life.
What could go wrong: This is a small, single-center phase 2 study without a control group, so results may not be widely applicable. Chemotherapy carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myeloid sarcoma refractory anemia with excess blasts in transformation therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT ACUTE MYELOID LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA THERAPY-RELATED ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Locations

University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.